Kentucky Derby 2025: Mike Tirico addresses allergic reaction, explains how nut allergy caused him to miss race
The 151st Kentucky Derby went on as planned Saturday, but without one of its most famous voices. NBC Sports broadcaster Mike Tirico was unable to provide coverage of the event due to an allergic reaction.
Ahmed Fareed stepped in for Tirico, who later revealed a "significant reaction" to his nut allergy caused him to miss the event. Tirico provided more insight into Saturday's absence during an appearance on "Today" on Monday.
"I ate something that had a nut in it and had a nut allergy, causing your throat and your nose all that stuff to kind of clog up and swell. It affects your breathing a little bit, so, wasn't feeling well, couldn't go on with the show" - Mike Tirico on 'Today' pic.twitter.com/YlLrWRAiNH
— Awful Announcing (@awfulannouncing) May 5, 2025
Tirico, 58, explained he's dealt with a nut allergy his entire life. Because of that, Tirico said he regularly reads food labels and informs restaurants of the allergy when he goes out to eat. While snacking on foods ahead of the Kentucky Derby, however, Tirico accidentally consumed something that had a nut in it.
ADVERTISEMENT
Advertisement
Tirico said his nose and throat "clogged up" and swelled. He added that the allergy can affect your breathing as well. Tirico decided he could not perform his duties as a broadcaster due to the reaction. He took an EpiPen shot — a common treatment for people experiencing an allergic reaction — and was seen by EMTs.
The treatment worked for Tirico, who said he was feeling better by Saturday evening.
May is Food Allergy Awareness Month and roughly 33 million Americans have some type of food allergy. A 2024 study by Food Allergy Research & Education estimates roughly 6.2 million people in the United States are allergic to peanuts and 3.9 million people in the U.S. are allergic to tree nuts.
Tirico encouraged others with food allergies to always be curious, read food labels and ask questions about food, especially when they have not prepared it themselves.
Tirico is a long-time broadcaster who has called just about every sport. He's the lead play-by-play announcer for "Sunday Night Football" and performs that same role during NBC's coverage of the NBA. He took over as the voice of NBC's Kentucky Derby coverage in 2017.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News24
6 hours ago
- News24
Red tape stops SA kids from getting ADHD meds
Many kids in South Africa, especially those who can't afford monthly doctor's visits, don't access their attention deficit and hyperactivity disorder medication regularly. It's time that we change that script, argues psychiatrist Renata Schoeman. Attention deficit and hyperactivity disorder (ADHD) affects between 5% and 7% of schoolgoing children, but because doctors can only prescribe treatment for a month at a time, many kids in South Africa, especially those who can't afford monthly doctor's visits, don't access medication regularly. Methylphenidate, a central nervous system stimulant that can significantly reduce symptoms in about 70% of users with the condition and that the World Health Organisation (WHO) recommends for the treatment of ADHD, helps people with ADHD to concentrate better, and to be less impulsive and overactive. Gold standard Studies have shown that when the methylphenidate - the gold standard for ADHD treatment - is used correctly, children's school marks improve and they become better equipped to develop social skills. In other words, effective ADHD treatment doesn't just help schoolgoers with ADHD to sit still and focus in class, but it also supports them to learn and socialise - outcomes which form the foundation of a healthy and productive adulthood. Methylphenidate is, however, classified as a schedule six drug in South Africa, placing it in the same regulatory category as medicines with a high potential for abuse. Pharmacies are, therefore only allowed to dispense the medicine to people with doctors' prescriptions, and by law, physicians can only prescribe 30 days' worth of methylphenidate treatment at a time. This means patients need to visit their doctor each month for a new prescription. In the private sector, they'd need to pay for a doctor's visit each month, in addition to paying for the medication. In the public sector, patients would need to take a day each month to queue up at their local clinic - and they'd have to make sure a doctor, as opposed to only nurses, is available at their health facility. The current scheduling, as a result, creates huge administrative and financial difficulties for patients and caregivers when they try to get treated, especially for those navigating ADHD's very symptoms: executive dysfunction, forgetfulness and inattention. Daily realities As a psychiatrist working in both the public and private healthcare sector, I've seen first-hand the toll that untreated ADHD takes on children, adults and families - from fractured educational journeys to unemployment, depression, addiction and even suicide. These are not theoretical risks but daily realities for many South Africans. Yet, one of the biggest obstacles that lock people out of treatment - our own healthcare policies - remains unchanged. LISTEN | LISTEN | Do ADHD meds work to cram during exams? It's time for us to change that script. A 2024 qualitative study with 23 South African stakeholders, which included healthcare professionals, pharmacists, regulators, patients and caregivers, revealed they did not see the current scheduling as an effective way to prevent misuse and illegal use. Instead, participants said, classifying methylphenidate a schedule 6 drug ' negatively impacts on treatment adherence '. Our medicines regulator, the South African Health Products Regulatory Authority (Sahpra) must urgently review the scheduling of methylphenidate to consider rescheduling it to a schedule five drug, which will allow doctors to prescribe six-monthly scripts. Schedule 5 medicines are medications with a low to moderate potential for abuse or dependence. Here are four reasons why methylphenidate should be a schedule 5 medication. More people with ADHD will get treated ADHD is not rare - a review of 53 research studies shows it affects 7.6% of children between 3 and 12 years and 5.6% of teens between 12 and 18. In 65% of cases, children's ADHD persists, at least partially, into adulthood. While we rightly invest in treating chronic conditions like diabetes and hypertension, we continue to overlook the profound, lifelong impact of untreated ADHD. Studies have confirmed that people with ADHD have a higher chance to also develop other psychiatric disorders such as anxiety or depression, they're far more likely to suffer from substance use disorders, to have accidental injuries, underachieve in school, be unemployed, become gamblers, fall pregnant as teenagers, die by suicide or die early. These factors contribute to the burden of disease and consequent stress on the health system - but most importantly, they reduce the quality of life of people with ADHD and their families. Medication can change this, yet access is limited. In many poorer communities, virtually no children who need treatment are receiving it. Although stigma and the cost of methylphenidate (on average, in today's terms, between R700 and R1 000 for a month's treatment in the private sector) play a role in making treatment harder to get, having it classified as a schedule 6 drug plays a big part in making the medication inaccessible - and it affects people in rural areas, the unemployed, and those without medical aid the most, which further widens the treatment gap between public and private healthcare sectors. Current scheduling does not prevent abuse Opponents of rescheduling often cite concerns about misuse - especially among tertiary students using methylphenidate for academic enhancement. Although these concerns are valid, evidence suggests that the current schedule 6 classification does little to prevent non-medical use. In fact, studies show that 28.1% of medical students have used methylphenidate without a prescription. This raises an uncomfortable truth: those determined to misuse the drug will find ways to do so, regardless of scheduling. One South African study, showed that of the 11.3% of students who reported having used methylphenidate in the past year, only 27.3% had been diagnosed with ADHD. Despite this, two-thirds obtained their medication through doctors' prescriptions, just under a third got it from friends and 6.1% bought it illegally. Meanwhile, genuine patients - particularly children and teenagers - are penalised by overly restrictive policies that reduce access to the very tools designed to help them succeed. We must ask ourselves: is the current scheduling preventing abuse, or is it merely restricting access for those who need it most? If the answer is the latter, then we have an ethical obligation to change course. Rescheduling does not mean deregulation. It means creating a more nuanced, risk-based framework - one that acknowledges both the need for control and the realities of living with a chronic disorder. More people will take their medication correctly How well someone adheres to their medication determines, to a large extent, how well the medicine works for them. But studies show between 13% to 64% of people with ADHD and who often use methylphenidate, don't use their medication as prescribed. For people with ADHD - with symptoms that impair their ability to organise, plan and follow through - the monthly schedule 6 script requirement can become a self-defeating cycle. The very condition we are trying to treat creates challenges in adhering to its treatment. LISTEN | ADHD cases are genetic. Can you outgrow it? Unsurprisingly, participants in the 2024 stakeholder study mentioned earlier in this article, viewed the current scheduling as counterproductive, and 'expressed their support for the convenience of six-monthly scripts for obtaining treatment'. Stakeholders argued that overall adherence would improve by reducing administrative challenges such as the need to take time off work and arrange monthly doctors' visits. Moreover, research shows, people with ADHD who use their medication correctly, are also more likely to adhere to medication for other conditions, for instance diabetes or HIV infection, that they may have. Improving adherence to ADHD medication therefore does not only improve the quality of patients' lives, but also lessens the burden on our health system overall. The state is doing same thing for antidepressants and anti-anxiety meds ADHD medication is not the only psychiatric medicine that needs rescheduling. South Africa's current HIV plan for 2023–2028 recommends that certain antidepressants and anti-anxiety medications are descheduled from schedule five drugs - which only doctors can prescribe - to schedule 4 drugs, so that specially trained nurses are able to prescribe them. Research has shown that there's a high chance for someone with HIV to develop depression or anxiety; these conditions are associated with people with HIV taking their medicine less regularly. But South Africa's government health system - which most HIV-positive people in the country use to get their treatment - doesn't have nearly enough doctors to staff clinics full-time. Instead, nurses run such clinics, with doctors only doing shifts once or twice a week. Getting nurses to diagnose mental health conditions and to prescribe treatment, will mean that patients won't have to return for doctors' appointments to get treated. Policy is never value neutral. It reflects what we, as a society, choose to prioritise. In the case of ADHD, we must choose inclusion over exclusion, access over fear, and healing over harm. Rescheduling methylphenidate is not about giving up control; it's about restoring agency to patients, families and clinicians alike. Sahpra response from CEO Boitumelo Semete-Makokotlela: Sahpra is open to the rescheduling of scheduled substances. For this to happen, either the manufacturer of a medicine or anyone in the scientific community who has data for us to consider has to submit a request for rescheduling, along with the required scientific and clinical data. We'll have our names and scheduling committee, as well as our clinical committee, review the submissions. We would also consider additional data, outside of what would have been provided, and then make a decision. This process takes about 120 days. - Professor Renata Schoeman is a Cape Town-based psychiatrist and the co-author of South Africa's ADHD management guidelines and chairs the SA Society of Psychiatrists special interest group for ADHD. She serves on the ministerial advisory committee for mental health and heads up the healthcare leadership MBA specialisation stream at Stellenbosch University. - This story was produced by the Bhekisisa Centre for Health Journalis m. Sign up for the newsletter. Disclaimer: News24 encourages freedom of speech and the expression of diverse views. The views of columnists published on News24 are therefore their own and do not necessarily represent the views of News24.
Associated Press
6 hours ago
- Associated Press
Discovered.TV and MHTN Forge Strategic Alliance to Elevate Mental Health Awareness
has partnered with the Mental Health Television Network (MHTN) to promote and expand access to mental health education. 'Our partnership with empowers us to reach wider communities, increase mental health literacy, and inspire positive change.'— Kieran Clarke, Co-Founder & CEO of MHTN SANTA CRUZ, CA, UNITED STATES, June 4, 2025 / / -- a global media streaming platform, has partnered with the Mental Health Television Network (MHTN) to expand access to mental health education and promote global well-being. This collaboration, launched during Mental Health Awareness Month, will leverage patented Enhanced Content Sharing Platform (ECSP) and MHTN's expert-driven content to reach over 70 million viewers across 2,000+ websites and streaming platforms, including iOS, Android, Roku, and more. 'Our partnership with empowers us to reach wider communities, increase mental health literacy, and inspire positive change,' said Kieran Clarke, Co-Founder & CEO of MHTN. ' is deeply committed to transforming mental health conversations,' added Charles Pankey, CEO of 'Together with MHTN, we aim to make a real difference worldwide.' Key Initiatives: Educational Programming: Streaming MHTN's mental health-focused shows. Expert Content Creation: Curated, evidence-based resources. Global Awareness Campaigns: Joint efforts to destigmatize mental health. About is a patented ECSP platform supporting creators with fair revenue sharing and innovative video technology. Learn more at About MHTN The Mental Health Television Network delivers curated, evidence-based content to normalize mental health conversations and provide accessible support. Discovered USA Inc. +1 917-328-9739 [email protected] Visit us on social media: LinkedIn Instagram Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
a day ago
- Yahoo
What to know about invasive ant with fatal sting reported in multiple states
The Joro spider, Asian long-horned beetle and spotted lanternfly have company this summer. A "sneaky" invasive species that has a potentially deadly sting continues to spread across the U.S. and can be found in more than a dozen states, according to experts. Asian needle ants were first detected in the U.S. almost a century ago, but the species has continued to expand its reach, primarily throughout the Southeast, and this pest could potentially be deadly to humans, according to Dan Suiter, a professor of urban entomology at the University of Georgia. "It injects venom that can harm you. Its sting can be life threatening," Suiter recently told the university. Suiter added that people who have adverse reactions to bee and ant stings are especially vulnerable and could go into anaphylactic shock from the needle ant's sting. Anaphylaxis is a potentially life-threatening allergic reaction that can occur within seconds of being exposed to something you're allergic to, such as a sting, according to the Mayo Clinic. "If you suffer from anaphylaxis, you should really know what this ant looks like," Suiter says. "And it might be smart to carry an EpiPen." Suiter urged people to be vigilant for these invasive species, especially with ant populations peaking later this summer. What are Asian needle ants? Asian needle ants are technically known as Brachyponera chinensis – roughly translated as "short, wicked ant from China" – but their native range also includes Japan and the Koreas, according to the U.S. Forest Service. The insect was first discovered in the U.S. in 1932 in Georgia, but has only recently started to "cause problems in North America after being relatively unnoticed for many years," the U.S. Forest Service says. The pest has now been detected all the way from Washington state to Florida, according to the site as well as Mississippi State University, and the ant is recently getting more attention in Texas. Suiter says Asian needle ants are "sneaky" because they are less than a quarter of an inch long and are adept at hiding. "Unlike many invasive species that tend to colonize areas in the wake of natural or human disturbance, Asian needle ants are capable of invading undisturbed forest areas where they nest under and within logs and other debris, under stones, and in leaf litter," the U.S. Forest Service says. Environmental impacts According to Suiter, Asian needle ants wreak havoc in native environments. "They outcompete other ant species that are important to the ecology of that area," he says. Asian needle ants prey on other insects and are capable of displacing ant species that are critical for seed dispersal, according to the U.S. Forest Service. Researchers have documented large decreases in seed dispersal in forests where Asian needle ants are present. "Thus, this invasive species could have dramatic, long-term negative effects on forest understory," the service says. What should people do if they see Asian needle ants? Asian needle ants are about 0.2 inches in length, and dark brown or black with the end of the antennae and the legs being a lighter orange-brown, the U.S. Forest Service says. Other ant species can look similar, "so it takes an experienced eye to positively identify them," the service says. Suiter says that you can send a photograph or a specimen to a local University of Georgia Extension office, which can help with identification. The public can also contact a professional to come out and bait for the ants, he says. The U.S. Forest Service advises people to avoid the pest and to be especially vigilant in areas with logs and rotting or rocks were the ants can nest. "Unfortunately, as with many invasive species, it appears Asian needle ants are here to stay," the service says. Kristi Noem says "we are not going to let a repeat of 2020 happen" amid L.A. crackdown Magic in the dark: The fantastical worlds of Lightwire Theater Barbara becomes first hurricane of 2025 season to form in Pacific Ocean
